Research programme: anti-estrogen compounds - AVAX Technologies

Drug Profile

Research programme: anti-estrogen compounds - AVAX Technologies

Alternative Names: 6-MCDF; Alkyl-PCDFs research programme - AVAX Technologies; Anti-estrogen technologies research programme - AVAX Technologies; Polychlorodibenzofurans research programme - AVAX Technologies

Latest Information Update: 16 Mar 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Texas A&M University
  • Developer AVAX Technologies; Texas A&M University
  • Class
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jul 2005 AVAX is exploring opportunities to license out its compounds from this programme to another company
  • 12 Nov 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 26 Feb 2001 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top